Latest News

Nuclera receives £500k seed-funding investment

Nuclera Nucleics Ltd. received an initial investment of £500k ($822k) for the development of a next-generation synthesis platform. 

Nuclera Nucleics is a next-generation DNA synthesis company, changing the paradigm of long DNA synthesis by enabling efficient synthesis of long strands of DNA in short timeframes. The Nuclera platform will make long DNA strands a readily available tool, and thus help expand research horizons and accelerate R&D of nucleic acid based pharmaceuticals.

Want to know more about our mission to change synthetic biology?

Our mission is simple: provide high-quality genes and proteins at your benchtop.

Get in touch